No profile data available.
Crescent Biopharma, Inc. (CBIO) is a healthcare company in the additional cancer treatment drugs industry, based in Waltham, United States, with about 69 full-time employees.
In Q2 2025 (the quarter ended June 30, 2025) revenue was $0. Its market capitalization was $553.86 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. , Ltd. for the development and commercialization of oncology therapeutics.
$553.86 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Nuvectis Pharma, Inc. (NVCT), Aura Biosciences, Inc. (AURA), CytomX Therapeutics, Inc. (CTMX), Allogene Therapeutics, Inc. (ALLO).